The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer
biorxiv(2023)
摘要
Background Notch signaling has been shown to mediate treatment resistance and support cancer stem cells (CSCs) in endocrine-resistant estrogen receptor positive (ER+) and triple negative breast cancers (TNBCs). The clinical development of GSIs, first generation Notch inhibitors, has been hindered by lack of Notch specificity and dose-limiting toxicity. Here we describe the safety and efficacy of a first-in-class, clinical stage, orally available small molecule pan-Notch inhibitor, CB-103. Due to its unique mode of action, CB-103 doesn’t induce GI toxicities noted with GSIs. There is a critical need for effective, safe, targeted therapies for patients with endocrine-refractory metastatic breast cancer. Recently approved targeted therapies for TNBC are only effective for a subset of patients. Moreover, GSI-resistant, constitutively activating Notch1 or Notch2 mutations are observed in ∼10% of TNBC. Our study elucidating the synergy of CB-103 with fulvestrant and paclitaxel in preclinical models of both hormone-refractory ER+ BC and TNBC respectively provides a novel and unique opportunity to address major unmet therapeutic needs.
Methods CB-103 was screened in combination with a panel of anti-neoplastic drugs. We evaluated the anti-tumor activity of CB-103 with fulvestrant in ESR1-mutant (Y537S), endocrine-resistant BC xenografts. In the same model, we examined anti-CSC activity in mammosphere formation assays for CB-103 alone or in combination with fulvestrant or palbociclib. We also evaluated the effect of CB-103 plus paclitaxel on primary tumors and CSC in GSI-resistant TNBC model HCC1187. Comparisons between groups were performed with two-sided unpaired Student’s t -test. One-way or two-way ANOVA followed by Tukey’s post analysis was performed to analyze in vivo efficacy study results.
Results CB-103 showed synergism with fulvestrant in ER+ cells and with paclitaxel in TNBC cells. CB-103 combined with fulvestrant or paclitaxel potently inhibited mammosphere formation in both models. Combination of CB-103 and fulvestrant significantly reduced tumor volume in an ESR1-mutant, endocrine-resistant BC model. In a GSI-resistant TNBC model, CB-103 plus paclitaxel significantly delayed tumor growth compared to paclitaxel alone.
Conclusions Our data indicate that CB-103 is an attractive candidate for clinical investigation in endocrine resistant, recurrent breast cancers with biomarker-confirmed Notch activity in combination with SERDs and/or CDKis and in TNBCs with biomarker-confirmed Notch activity in combination with taxane-containing chemotherapy regimens.
### Competing Interest Statement
The authors have declared no competing interest.
* ANOVA
: Analysis of variance
BC
: Breast Cancer
CDK
: Cyclin-dependent kinase
Cmax
: Maximal plasma concentration
CR
: Complete response
CSCs
: Cancer Stem Cells
DMSO
: Dimethyl sulfoxide
ER+
: Estrogen receptor positive
ESR1
: Estrogen Receptor Gene α
FCS
: Fetal Calf Serum
GSIs
: gamma-secretase inhibitors
H&E
: Hematoxylin and Eosin
LC-MS
: Liquid chromatography–Mass Spectrometry
MAPK
: Mitogen-activated protein kinase
MZB cells
: Marginal Zone B cells
PD
: Pharmacodynamics
PDX
: Patient-derived xenograft
PI3K
: Phosphoinositide 3-kinase
PK
: Pharmacokinetics
PR
: Partial response
PR+
: Progesterone receptor positive
SD
: Stable disease
SERD
: Selective Estrogen Receptor Disruptor
TNBC
: Triple Negative Breast Cancer
TV
: Tumor volume
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要